Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/206294
COMPARTIR / EXPORTAR:
SHARE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Navarro Medrano, Pilar | es_ES |
dc.contributor.author | Martínez-Bosch, Neus | es_ES |
dc.contributor.author | Orozco, Carlos A. | es_ES |
dc.contributor.author | Barranco, Luis E. | es_ES |
dc.contributor.author | Guerrero, Pedro E. | es_ES |
dc.contributor.author | Vinaixa, Judith | es_ES |
dc.contributor.author | Dalotto-Moreno, Tomás | es_ES |
dc.contributor.author | Moreno-Estellés, Mireia | es_ES |
dc.contributor.author | Visa, Laura | es_ES |
dc.contributor.author | Iglesias, Mar | es_ES |
dc.contributor.author | Djurec, Magdolna | es_ES |
dc.contributor.author | Poirier, Françoise | es_ES |
dc.contributor.author | Gabius, Hans-Joachim | es_ES |
dc.contributor.author | Oldfield, Lucy | es_ES |
dc.contributor.author | Neoptolemos, John P. | es_ES |
dc.contributor.author | Greenhalf, William | es_ES |
dc.contributor.author | Earl, Julie | es_ES |
dc.contributor.author | Carrato, Alfredo | es_ES |
dc.contributor.author | Costello, Eithne | es_ES |
dc.contributor.author | Fernández-Zapico, E. | es_ES |
dc.contributor.author | Hwang, Rosa F. | es_ES |
dc.contributor.author | Guerra, Carmen | es_ES |
dc.contributor.author | Rabinovich, Gabriel A. | es_ES |
dc.date.accessioned | 2020-04-02T11:31:57Z | - |
dc.date.available | 2020-04-02T11:31:57Z | - |
dc.date.issued | 2019-09-19 | - |
dc.identifier.citation | XVI Reunión de la Asociación Española de Pancreatología (2019) | es_ES |
dc.identifier.uri | http://hdl.handle.net/10261/206294 | - |
dc.description | Trabajo presentado en la XVI Reunión de la Asociación Española de Pancreatología, celebrada en Bilbao (España), del 19 al 21 de septiembre de 2019 | - |
dc.description.abstract | Background: Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal tumor types, with extremely low survival rates due to late diagnosis and resistance to standard therapies. Identification of new molecular targets and biomarkers is therefore an urgent need to improve this pessimistic scenario. Here we analyze the potential use of galectin-1 (Gal1), a glycan-binding protein that is highly overexpressed in PDA stroma, as therapeutic target and biomarker for PDA. Methods: To study the potential use of Gal1 as therapeutic target, effects of Gal1 inhibition has been tested using genetically engineered mouse models (Gal1 knockout mice and a KRas-driven mouse model of PDA) and a human cell-based system. To analyze whether Gal1 can be used as PDA biomarker, its levels were determined by ELISA in plasma from healthy controls and patients diagnosed with PDA, using three independent cohorts Results: Both in mouse models and in a human setting, inhibition of Gal1 leads to impaired tumor formation and metastasis, through modulation of multiple events including proliferation, angiogenesis and immune response. In addition, we found that plasma Gal-1 levels were significantly increased in PDA patients as compared to controls and that high levels of Gal-1 were associated with lower survival in patients with non-resected tumors. Conclusions: Gal1 plays a key role in PDA development and progression, highlighting the high therapeutic value of Gal1 inhibition in PDA treatment. Moreover, detection of Gal1 circulating levels shows a strong potential to be used as a novel biomarker for detection and prognostics of PDA patients. | - |
dc.language | eng | - |
dc.rights | closedAccess | - |
dc.title | Galectin-1 is a novel therapeutic target and diagnostic/prognostic biomarker for pancreatic cancer | es_ES |
dc.type | comunicación de congreso | es_ES |
dc.date.updated | 2020-04-02T11:31:58Z | - |
dc.relation.csic | Sí | es_ES |
dc.type.coar | http://purl.org/coar/resource_type/c_5794 | es_ES |
item.openairetype | comunicación de congreso | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.cerifentitytype | Publications | - |
Aparece en las colecciones: | (IIBB) Comunicaciones congresos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
Page view(s)
222
checked on 24-abr-2024
Download(s)
31
checked on 24-abr-2024
Google ScholarTM
Check
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.